Le Lézard
Classified in: Covid-19 virus
Subjects: Conference, Trade Show, Webcast

Tapestry, Inc. to Present at the Bernstein Strategic Decisions Conference


Tapestry, Inc. (NYSE: TPR), a leading New York-based house of modern luxury accessories and lifestyle brands, today announced that Jide Zeitlin, Chairman and Chief Executive Officer, and Joanne Crevoiserat, Chief Financial Officer, will present at the Bernstein Strategic Decisions Conference on Thursday, May 28, 2020 at 4:00 p.m. ET.

The presentation will be webcast live, available to the general public and archived for a period of five business days. To access the presentation, log onto www.tapestry.com/investors or https://kvgo.com/AB/bernstein-tapestry-may-2020.

Tapestry, Inc. is a New York-based house of modern luxury lifestyle brands. The Company's portfolio includes Coach, Kate Spade and Stuart Weitzman. Our Company and our brands are founded upon a creative and consumer-led view of luxury that stands for inclusivity and approachability. Each of our brands are unique and independent, while sharing a commitment to innovation and authenticity defined by distinctive products and differentiated customer experiences across channels and geographies. To learn more about Tapestry, please visit www.tapestry.com. The Company's common stock is traded on the New York Stock Exchange under the symbol TPR.

This information to be made available in this press release may contain forward-looking statements based on management's current expectations. Forward-looking statements include, but are not limited to, the statements that can be identified by the use of forward-looking terminology such as "may," "will," "can," "should," "expect," "intend," "estimate," "continue," "project," "guidance," "forecast," "outlook," "roadmap," "anticipate," "excited," "moving," "leveraging," "capitalizing," "developing," "drive," "targeting," "assume," "plan," "build," "pursue," "maintain," "progress," "future," "emerge," "assure," "on track," "well positioned to," "look forward to," "looking ahead," "to acquire," "achieve," "strategic vision," "ongoing headwinds," "growth opportunities," "view," or comparable terms. Future results may differ materially from management's current expectations, based upon a number of important factors, including risks and uncertainties such as the impact of the Covid-19 pandemic, the ability to control costs and successfully execute our growth strategies, expected economic trends, the ability to anticipate consumer preferences, risks associated with operating in international markets, our ability to achieve intended benefits, cost savings and synergies from acquisitions, the risk of cybersecurity threats and privacy or data security breaches, and the impact of the CARES Act and other legislation, etc. Please refer to the Company's latest Annual Report on Form 10-K, quarterly report on 10-Q and its other filings with the Securities and Exchange Commission for a complete list of risks and important factors. The Company assumes no obligation to revise or update any such forward-looking statements for any reason, except as required by law.


These press releases may also interest you

at 08:35
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor...

at 08:25
NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the "Agreement"), dated April 25, 2024, to acquire a home care services company ("the...

at 08:20
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory...

at 08:09
Adyton Resources Corporation announces that it has filed its financial statements for the three and twelve months ended December 31, 2023 and accompanying Management Discussion and Analysis on its SEDAR profile at www.sedar.com. ...

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:00
The "Global Men's Health and Wellness Market: Analysis By Type, By Distribution Channel, By Region Size & Forecast with Impact Analysis of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering. In 2023, the...



News published on and distributed by: